|UroGen Pharma Welcomes New Board Member Kate Falberg|
Ra’anana, Israel, April 24, 2017: UroGen Pharma Ltd., a privately held, clinical stage biopharmaceutical company that is developing advanced non-surgical treatments to address unmet needs in the field of uro-oncology, announced today the appointment of Kathryn “Kate” Falberg to its Board of Directors, effective immediately. Ms. Falberg will also serve as the Chair of the Board’s Audit Committee.
Ms. Falberg brings extensive executive leadership and management experience in the life sciences industry. She most recently served as an Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals PLC. Previously, Ms. Falberg served as Senior Vice President, Finance and Strategy and Chief Financial Officer of Amgen. Ms. Falberg currently serves on the boards of Aimmune Therapeutics, aTyr Pharma, Axovant Sciences, BioMarin Pharmaceutical and The Trade Desk, and recently served on the board of directors of Medivation until its acquisition by Pfizer. Ms. Falberg holds a B.A. and M.B.A from UCLA, is a CPA, inactive, and a UCLA Certified Director.
Arie Belldegrun, MD, Urogen Pharma’s Chairman, commented, “We are extremely pleased to welcome Kate to the UroGen Board of Directors. Kate’s financial and industry expertise and track record make her an excellent choice for UroGen. We look forward to Kate’s contributions and benefitting from her counsel.”
Kate Falberg commented, “I am delighted to have the opportunity to join UroGen’s Board of Directors. UroGen’s dedicated team is developing important cutting edge treatments in the uro-oncology space and I look forward to providing financial leadership and operational guidance as the Company continues to grow.”
About UroGen Pharma Ltd.
UroGen Pharma is a clinical stage biopharmaceutical company developing advanced non-surgical, local treatments to address unmet needs in the field of urology, with a focus on uro-oncology. The Company has developed RTGel, a proprietary sustained release, hydrogel-based formulation for potentially improving the efficacy and safety profiles of existing drugs. UroGen Pharma’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen Pharma’s lead product candidates, MitoGel and VesiGel, are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade UTUC and bladder cancer. Moreover, UroGen Pharma has recently completed a worldwide licensing agreement with Allergan Pharmaceuticals International Limited, a wholly owned subsidiary of Allergan plc, for the use of RTGel with neurotoxins for the treatment of overactive bladder and related conditions. UroGen Pharma is headquartered in Israel and also maintains a corporate office in New York City.
Forward Looking Statements
This press release contains forward-looking statements. All statements contained herein other than statements of historical fact constitute forward-looking statements, including statements regarding UroGen Pharma’s business strategy, clinical development plan and operating plans. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: the timing and success of preclinical studies and clinical trials conducted by or on behalf of UroGen Pharma, including with respect to the efficacy and safety of its product candidates; UroGen Pharma’s ability to obtain and maintain regulatory approval of its product candidates, and the labeling for any approved products; the scope, progress, expansion and costs of developing and commercializing UroGen Pharma’s product candidates; UroGen Pharma’s ability to obtain and maintain intellectual property protection for its product candidates; UroGen Pharma’s anticipated growth strategies; UroGen Pharma’s expectations regarding competition; the anticipated trends and challenges in UroGen Pharma’s business and the markets in which it operates; UroGen Pharma’s ability to attract or retain key management and personnel; the size and growth of the potential markets for UroGen Pharma’s product candidates and its ability to serve those markets; the rate and degree of market acceptance of UroGen Pharma’s product candidates vis-à-vis alternative therapies; UroGen Pharma’s expectations regarding regulatory requirements; developments in applicable regulatory regimes; UroGen Pharma’s ability to enter into and maintain collaborations; and the manner in which UroGen Pharma intends to use its cash resources and the sufficiency thereof. Moreover, UroGen Pharma operates in a very competitive and rapidly changing environment in which new risks emerge from time to time. It is not possible for UroGen Pharma’s management to predict all risks, nor can they assess the impact of all factors on its business or the extent to which any such factor or combination of factors may cause actual results to differ materially from those contained herein. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur, and UroGen Pharma’s actual results could differ materially and adversely from those anticipated or implied by the forward-looking statements contained herein. UroGen Pharma undertakes no obligation to update any such forward-looking statements after the date hereof to conform to actual results or changes in expectations.
Stephanie Carrington, ICR, Inc.